К вопросу о безопасности применения антидепрессантов в кардиологической практике(обзор зарубежной литературы)
Психические расстройства в общей медицине. №4 2008
К вопросу о безопасности применения антидепрессантов в кардиологической практике(обзор зарубежной литературы)
Т.В.Головачева, В.В.Скворцов, К.Ю.Скворцов
Кафедра терапии ФПК ППС ГОУ ВПО "Саратовский ГМУ Росздрава", кафедра пропедевтики внутренних болезней ГОУ ВПО "Волгоградский ГМУ Росздрава"
Стр. 51-65
3428 просмотров
Опубликовано: 25 ноября 2008
Аннотация / Abstract
Введение
Депрессия – частое аффективное расстройство, истинная распространенность которого в населении окончательно неизвестна. Так, А.Б.Смулевич, А.Л.Сыркин и соавт. (2005 г.) опубликовали данные о том, что заболеваемость депрессиями на сегодняшний день составляет 3%, а риск заболеть депрессией в течение всей жизни – 20% [1]. В 1994 г. в эпидемиологическом исследовании National Comorbidity Survey, изучавшем распространенность и факторы риска “большой” депрессии per se и “большой” коморбидной депрессии, было показано, что приблизительно 17% американцев испытывали в течение жизни “тяжелую” депрессию, а около 10% населения США – в течение последних 12 мес [2, 3].
Термин “депрессивный эпизод” объединяет три понятия: “большая” депрессия, униполярная (монополярная) депрессия и автономная депрессия. Отечественные и зарубежные психиатры характеризуют “большое” депрессивное расстройство как состояние, когда в течение по меньшей мере 2 нед имеются пять следующих симптомов или более: сниженное настроение большую часть дня, значительное снижение интереса и/или чувства удовольствия от всех или практически всех видов повседневной активности, изменения аппетита (как снижение, так и повышение) с изменением массы тела или без такового, инсомния/гиперсомния, психомоторная ажитация/заторможенность, чувство опустошенности/потери энергии, чувство бесцельности существования/крайне выраженное чувство собственной вины, снижение умственной активности и снижение возможности концентрировать внимание, принимать решение, суицидальные мысли или мысли о смерти [1, 4].
Патофизиология.
Патофизиологические механизмы, лежащие в основе депрессивных расстройств, являются многофакторными и малоизученными. Было предложено несколько гипотез. Наибольшее признание получила “моноаминовая” гипотеза, “отправной точкой” которой послужил эмпирический факт, ...
Введение
Депрессия – частое аффективное расстройство, истинная распространенность которого в населении окончательно неизвестна. Так, А.Б.Смулевич, А.Л.Сыркин и соавт. (2005 г.) опубликовали данные о том, что заболеваемость депрессиями на сегодняшний день составляет 3%, а риск заболеть депрессией в течение всей жизни – 20% [1]. В 1994 г. в эпидемиологическом исследовании National Comorbidity Survey, изучавшем распространенность и факторы риска “большой” депрессии per se и “большой” коморбидной депрессии, было показано, что приблизительно 17% американцев испытывали в течение жизни “тяжелую” депрессию, а около 10% населения США – в течение последних 12 мес [2, 3].
Термин “депрессивный эпизод” объединяет три понятия: “большая” депрессия, униполярная (монополярная) депрессия и автономная депрессия....
Материал для специалистов
Полный текст статьи доступен только зарегистрированным пользователям.
Вход / Регистрация- 1. Смулевич А.Б., Сыркин А.Л., Дробижев М.Ю., Иванов С.В. Психокардиология. М.: Медицинское информационное агентство, 2005.
- 2. Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiat 1994; 51: 8–19.
- 3. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiat 1994; 151: 979–86.
- 4. The American Psychiatric Association. Mood disorders. The diagnostic and statistical manual of mental disorders, 4th ed, Washington, DC: American Psychiatric Association. 1994; 317–91.
- 5. Benowitz NL. Antihypertensive agents. Basic and clinical Pharmacology, 8th ed. B.G.Katzung, ed. New York: Lange Medical Books/McGraw-Hill, 2001; 155–80.
- 6. Akiskal HS. Mood disorders: introduction and overview. Kaplan&Sadock’s comprehensive textbook of psychiatry, 7th ed. B.J. Sadock and V.A., eds. Philadelphia: Lipincott Williams & Wilkins, 2000; 1284–440.
- 7. Stahl SM. Depression and bipolar disorders. Neuroscientific basis and practical application, 2nd ed. Cambridge: Cambridge University Press, 2000; 135–97.
- 8. Krishnan KR, Delong M, Kraemer H et al Comorbidity of depression with other medical diseases in elderly. Biol. Psychiatry. 2002; 52: 559–88.
- 9. Jiang W, Alexander J, Christopher E et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001; 161: 1849–56.
- 10. Ariyo A, Haan M, Tangen C et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Afor the Cardiovascular Health Study Collaborative Research Group. Circulation 2000; 102: 1773–9.
- 11. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91: 999–1005.
- 12. Schleifer S, Macari-Hinson M, Coyle D et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149: 1785–9.
- 13. Carney R, Rich M, teVelde A et al. Prevalence of major depressive disorder in patients receiving b-blocker therapy versus other medications Am J Med 1987; 83: 223–6.
- 14. Zuccala G, Cocchi A, Carbonin P. The impact of depression on self-perceived health status J Am Geriatr Soc 1995; 43: 198–9.
- 15. Чазов Е.И., Оганов Р.Г., Погосова Г.В. и др. Клинико-эпидемиологическая программа изучения депрессии в кардиологической практике: у больных артериальной гипертонией и ишемической болезнью сердца (КООРДИНАТА): результаты многоцентрового исследования. Кардиология. 2007; 3: 28–37.
- 16. van den Brink R, van Melle J, Honig A et al.Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the myocardial infarction and depression-intervention trial (MIND-IT) Am Heart J 2002; 144: 219–25.
- 17. Rozanski A, Blumenthal J, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999; 99: 2192–217.
- 18. Sesso H, Kawachi I, Vokonas P, Sparrow D. Depression and the risk of coronary heart disease in the normative aging study. Am J Cardiol 1998; 82: 851–6.
- 19. Ferketich A, Schwartzbaum J, Frid D, Moeschberger M. Depression as an antecedent to heart disease among women and men in the NHANES I study Arch Intern Med 2000; 160: 1261–8.
- 20. Roose S, Dalack G, Woodring S. Death, depression, and heart disease J Clin Psychiatr 1991; 52 (suppl.): 34–9.
- 21. Sullivan M, LaCroix A, Russo J et al. Depression in coronary heart disease: what is the appropriate diagnostic threshold? Psychosomatics 1999; 40: 286–92.
- 22. Ford D, Meal L, Chang P et al. Depression as a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med 1998; 158: 1422–6.
- 23. Creed F. The importance of depression following myocardial infarction. Heart 1999; 82: 406–8.
- 24. Cohen H, Gibson G, Alderman M. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000; 108: 2–8.
- 25. Lapane K, Zierler S, Lasater T et al. Is the use of psychotropic drugs associated with increased risk of ischemic heart disease? Epidemiology 1995; 6: 376–81.
- 26. Yusuf S. Howken S, Ounpuu S, on behalf of the INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–52.
- 27. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. A. Rosengren, S. Hawken, S. Ounpuu et al. Lancet 2004; 364: 953–62.
- 28. Ballenger J, Davidson J, Lecrubier Y et al. and the International Consensus Group on Depression and Anxiety. Consensus statement on depression, anxiety, and cardiovascular disease. J Clin Psychiatry 2001;62 (suppl. 8): 24–7.
- 29. Havranek E, Ware M, Lowes B. Prevalence of depression in congestive heart failure. Am J Cardiol 1999; 84: 348–50.
- 30. Murberg T, Bru E, Aarsland T, Svebak S. Functional status and depression among men and women with congestive heart failure. Int J Psychiatry Med 1998; 28: 273–91.
- 31. Koenig H. Depression in hospitalized older patients with congestive heart failure. Gen Hosp Psychiatry 1998; 20: 29–43.
- 32. Fraticelli A. Congestive heart failure in the elderly requiring hospital admission. Arch Gerontol. Geriatr 1996; 23: 225–38.
- 33. Krumholz H, Butler J, Miller J et al. Prognostic importance of emotional support for elderly patients hospitalized with heart failure. Circulation 1998; 97: 958–64.
- 34. Frasure-Smith N, Lesperance F. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 270 (15): 1819–25.
- 35. Carney R, Rich M, teVelde A et al. Major depressive disorder in coronary artery disease. Am J Cardiol 1987; 60: 1273–5.
- 36. McKhann G, Borowicz L, Goldborough M et al. Depression and cognitive decline after coronary artery bypass grafting. Lancet 1997; 349: 1282–4.
- 37. Con A, Linden W, Thompson J, Ignaszewski A. The psychology of men and women recovering from coronary artery bypass surgery. J Cardiopulmonary Rehabil 1999; 19: 152–61.
- 38. Carney R, Freedland K, Rich M et al. Ventricular tachycardia and psychiatric depression in patients with coronary artery disease. Am J Med 1993; 95: 23–8.
- 39. Скворцов К.Ю., Головачева Т.В. Эффективность тофизопама (грандаксина) в лечении ИБС: клинико-инструментальное подтверждение. Клиническая фармакология и терапия 2001; 1: 52–5.
- 40. Panina G, Knot U, Nunziata E et al. Assessment of autonomic tone over a 24-hour period in patients with congestive heart failure. Am Heart J 1995; 129: 748–53.
- 41. Klingenheben T, Rapp U, Hohnloser S. Circadian variation of heart rate variability in postinfarction patients with and without life-threatening ventricular tachyarrhythmias. J Cardiovasc Electrophysiol 1995; 6: 357–64.
- 42. Shusterman V, Aysin B, Weiss R et al. Dynamics of low-frequency R-R interval oscillations preceding spontaneous ventricular tachycardia. Am Heart J 2000; 139: 126–33.
- 43. Lown B., Verrier R, Rabinowitz S. Neural and psychological mechanisms and the problem of sudden cardiac death. Am J Cardiol 1977; 39: 890–2.
- 44. Reich P, DeSilva R, Lown B, Murawski B. Acute psychological disturbances preceding life-threatening ventricular arrhythmias. JAMA 1981; 246: 233–5.
- 45. Brodsy M, Sato D, Iseri L et al. Ventricular tachycardia associated with psychological stress: the role of sympathetic nervous system. JAMA 1987; 257: 2064–7.
- 46. Peters R, McQuillan S, Resnik S, Gold M. Increased Monday incidence of life-threatening ventricular arrhythmias: experience with a third-generation implantable defibrillator. Circulation 1996; 94: 1346–9.
- 47. Lehofer M, Moser M, Hoehn-Saric R et al. Major depression and cardiac autonomic control. Biol Psychiatry 1997; 42: 914–9.
- 48. Golino P, Piscione F, Willerson J. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med 1991; 324:641–8.
- 49. Vikenes K, Farstad M, Nordrehaug J. Serotonin is associated with coronary artery disease and cardiac events. Circulation 1999; 100: 483–9.
- 50. Harrigan R, Brady W. ECG abnormalities in tricyclic antidepressant ingestion. Am J Med 2000; 108: 2–8.
- 51. Giardina E, Johnson L, Vita J et al. Effect of imipramine and notriptyline on left ventricular function and blood pressure in patients treated for arrhythmias. Am Heart J 1985; 109: 992–8.
- 52. Giardina E, Barnard T, Johnson L et al. The antiarrhythmic effect of nortriptyline in cardiac patients with ventricular premature depolarizations. J Am Coll Cardiol 1986; 7: 1363–9.
- 53. Giardina E, Cooper T, Suckow R, Saroff A. Cardiovascular effects of doxepine in cardiac patients with ventricular arrhythmias. Clin Pharmacol Ther 1987; 42: 20–7.
- 54. Jo S, Youm J, Lee C et al. Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyl. Br J Pharmacol 2000; 129: 1474–80.
- 55. Teschemacher A, Seward E, Hancox J, Witchel H. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 1999; 128: 479–85.
- 56. Feenstra J, Grobbee D, Remme W, Stricker B. Drug-induced heart failure. J Am Coll Cardiol 1999; 33: 1152–62.
- 57. Veith R, Raskind M, Barnes R et al. Tricyclic antidepressants and supine, standing, and exercise plasma norepinephrine. Clin Pharmacol Ther 1983; 33: 763–9.
- 58. Glassman A, Bigger J Jr, Giardina E et al.Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet 1979; 1 (8114): 468–72.
- 59. Ruberman W, Weinblatt E, Goldberg J et al. Ventricular premature beats and mortality after myocardial infarction. N Engl J Med 1977; 297: 750–7.
- 60. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Am J Cardiol 1988; 61: 501–9.
- 61. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321: 406–12.
- 62. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The CAST Investigators. N Engl J Med 1991; 324: 781–8.
- 63. Effects of the antiarrythmic agent moricizine on survival after myocardial infarction. The CAST II Investigators. N Engl J Med 1992; 327: 227–33.
- 64. Roose S, Glassman A. Antidepressant choice in the patient with cardiac disease: lessons from the cardiac arrhythmias suppression trial (CAST) studies. J Clin Psychiatry 1994; 55 (suppl. A): 83–7.
- 65. Raskind M, Veith R, Barnes R, Gumbrecht G. Cardiovascular and antidepressant effects of imipramine in the treatment of secondary depression in patients with ischemic heart disease. Am J Psychiatry 1982; 139: 1114–7.
- 66. Veith R, Raskind M, Caidwell J et al. Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. N Engl J Med 1982; 306: 954–9.
- 67. Glassman A, Johnson L, Giardina E et al. The use of imipramine in depressed patients with congestive heart failure. JAMA 1983; 250: 1997–2001.
- 68. Roose S, Glassman A, Giardina E et al. Nortriptyline in depressed patients with left ventricular impairment. JAMA 1986; 256: 3253–7.
- 69. Roose S, Glassman A, Giardina E et al. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987; 44: 273–5.
- 70. Dietch J, Fine M. The effect of nortriptyline in elderly patients with cardiac conduction disease. J Clin Psychiatry 1990; 51: 57–5.
- 71. Cohn J, Wilcox C, Goodman L. Antidepressant efficacy and safety of trimipramine in patients with mild heart disease. Clin. Ther 1993; 15: 114–26.
- 72. Himmelhoch J, Schechtman K, Auchenbach R. The role of trazodone in the treatment of depressed cardiac patients. Psychopathology 1984; 17 (suppl. 2): 51–63.
- 73. Janowsky D, Curtis G, Zissook S et al. Ventricular arrhythmias possibly aggravated by trazodone. Am J Psychiatry 1983; 140: 796–7.
- 74. Roose S, Glassman A, Giardina E et al. Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. J Clin Psychopharmacology 1987; 7: 247–51.
- 75. Roose S, Dallack G, Glassman A et al. Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 1991; 148: 512–6.
- 76. Sheline Y, Freedland K, Carney R. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med 1997; 102: 54–9.
- 77. Isbister G, Prior F, Foy A. Citalopram-induced bradycardia and presyncope. Ann Pharmacother 2001; 35: 1552–5.
- 78. Catalano G, Catalano M, Epstein M, Tsambiras P. QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin. Neuropharacol 2001; 24: 158–62.
- 79. Neely J. Tonic clonic seizures and tachycardia induced by fluoxetine overdose. W V Med J 1998; 94: 283–5.
- 80. Gaudins A, Vossler C, Wang R. Fluoxetine-induced cardiotoxicity with response to bicarbonate therapy. Am J Emerg Med 1997; 15: 501–3.
- 81. McAnally L. Threlkeld K, Dreyling C. Case report of a syncopal episode associated with fluoxetine. Ann Pharmacother 1992; 26: 1090–1.
- 82. Spier S, Frontera M. Unexpected deaths in depressed medical inpatients treated with fluoxetine. J Clin Psychiatry 1991; 52: 377–82.
- 83. Roose S, Laghrissi-Thode F, Kennedy J et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279: 287–91.
- 84. Roose S, Glassman A, Attia E et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155: 660–5.
- 85. Strik J, Honig A, Lousberg R et al.Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psycosom Med 2000; 62: 783–9.
- 86. Shapiro A, Lesperance F, Frasure-Smith N et al. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT trial). Am Heart J 1999; 137: 1100–6.
- 87. Glassman A, O\'Connor C, Califf R et al. Sertraline treatment of major depression in patients with acute MI or unstable angina (the SADHART trial). JAMA 2002; 288: 701–9.
- 88. Stys A, Stys T. Current clinical application of heart rate variability. Clin Cardiol 1998; 21: 719–24.
- 89. Kleiger R, Miller J, Bigger J Jr., Moss A. Decreased heart rate variability and its association with mortality after myocardial infarction. Am J Cardiol 1987; 59: 256–62.
- 90. Carney R, Blumenthal J, Stein P et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001; 104: 2024–8.
- 91. McFariane A, Kamath K, Fallen E et al. Effect of sertraline on recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J 2001; 142: 617–23.
- 92. Laghrissi-Thode F, Wagner W, Pollock B et al. Elevated platelet factor 4 and b-thromboglobulin plasma levels in depressed ischemic heart disease. Biol. Psychiatry 1997; 42: 290–5.
- 93. Musselman D, Tomer A, Manatunga A et al.Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996; 153: 1313–17.
- 94. Pollock B, Laghrissi-Thode F, Wagner W. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000; 20: 137–40.
- 95. Nair G, Gurbel P, O\'Connor C et al. Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. Am J Cardiol 1999; 84: 321–3.
- 96. Pratt L, Ford D, Crum R et al. Depression, psychotropic medication, and risk of myocardial infarction. Circulation 1996; 94: 3123–9.
- 97. Чазов Е.И., Оганов Р.Г., Погосова Г.В. и др. Клинико-эпидемиологическая программа изучения депрессии в кардиологической практике: у больных артериальной гипертонией и ишемической болезнью сердца (КООРДИНАТА): первые результаты многоцентрового исследования. Кардиология. 2005; 11: 4–11.